Related Experiment Video
Updated: Nov 11, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
Lin Wang1,2, Dominik Aschenbrenner3,4, Zhiyang Zeng5
1Department of Gastroenterology, Pediatric Inflammatory Bowel Disease Research Center, Children's Hospital of Fudan University, Shanghai, China.
Abstract:
Spleen tyrosine kinase (SYK) is a critical immune signaling molecule and therapeutic target. We identified damaging monoallelic SYK variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK variants increased phosphorylation and enhanced downstream signaling, indicating gain of function. A knock-in (SYK-Ser544Tyr) mouse model of a patient variant (p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or transplantation of bone marrow from wild-type mice. Our studies demonstrate that SYK gain-of-function variants result in a potentially treatable form of inflammatory disease.
Insights
Gain-of-function variants in Spleen tyrosine kinase (SYK) cause immune deficiency and inflammatory disease. These SYK variants are treatable with SYK inhibitors or bone marrow transplantation.
Area of Science:
- Immunology
- Molecular Biology
- Genetics
Background:
- Spleen tyrosine kinase (SYK) is a key regulator of immune cell signaling.
- SYK is a validated therapeutic target for various immune-related disorders.
Purpose of the Study:
- To investigate the role of damaging SYK variants in human immune deficiency and inflammatory diseases.
- To characterize the functional consequences of identified SYK variants and evaluate therapeutic strategies.
Main Methods:
- Identified monoallelic SYK variants in patients with immune deficiency and multi-organ inflammation.
- Utilized a knock-in mouse model (SYK-Ser544Tyr) to study disease mechanisms.
- Assessed the efficacy of a SYK inhibitor and bone marrow transplantation in the mouse model.
Main Results:
- Six patients presented with immune deficiency, multi-organ inflammation (colitis, arthritis, dermatitis), and B cell lymphomas due to damaging SYK variants.
- SYK variants demonstrated increased phosphorylation and enhanced downstream signaling, indicating a gain-of-function.
- The SYK-Ser544Tyr mouse model recapitulated key features of the human disease.
- Disease manifestations in the mouse model were partially ameliorated by SYK inhibition and wild-type bone marrow transplantation.
Conclusions:
- Gain-of-function variants in SYK lead to a novel form of immune deficiency and inflammatory disease.
- These SYK-driven inflammatory conditions represent a potentially treatable clinical entity.
- Targeting SYK offers a therapeutic avenue for patients with these specific genetic variants.
Related Concept Videos
The JAK-STAT Signaling Pathway
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

